| Dr Michael J Lloyd, MD | |
|
1055 N 300 W Ste 204, Provo, UT 84604-3374 | |
| (801) 357-7373 | |
| (801) 357-7217 |
| Full Name | Dr Michael J Lloyd |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 20 Years |
| Location | 1055 N 300 W Ste 204, Provo, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124239009 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 7217390-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Utah Valley Hospital | Provo, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Utah Valley Eye Center Inc | 7810167392 | 13 |
News Archive
The Muscular Dystrophy Association today celebrated news of the U.S. Food and Drug Administration's decision to grant approval for nusinersen (brand name Spinraza), the first disease-modifying drug to treat the most common genetic cause of death in infants.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells.
A study by a joint research team including professor Kazuyo Tsuzuki of Toyohashi University of Technology, Department of Architecture and Civil Engineering, National Institute of Advanced Industrial Science and Technology and Asahi Kasei Homes revealed that airflow from an air conditioner stimulates the human body while sleeping and impacts on sleep conditions even if the mean airflow velocity is lower than an insensible level.
Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' health habits and connections to caregivers.
› Verified 6 days ago
| Entity Name | Utah Valley Eye Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902195605 PECOS PAC ID: 7810167392 Enrollment ID: O20110913000858 |
News Archive
The Muscular Dystrophy Association today celebrated news of the U.S. Food and Drug Administration's decision to grant approval for nusinersen (brand name Spinraza), the first disease-modifying drug to treat the most common genetic cause of death in infants.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells.
A study by a joint research team including professor Kazuyo Tsuzuki of Toyohashi University of Technology, Department of Architecture and Civil Engineering, National Institute of Advanced Industrial Science and Technology and Asahi Kasei Homes revealed that airflow from an air conditioner stimulates the human body while sleeping and impacts on sleep conditions even if the mean airflow velocity is lower than an insensible level.
Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' health habits and connections to caregivers.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael J Lloyd, MD 1055 N 300 W, Ste 204, Provo, UT 84604-3344 Ph: (801) 357-7373 | Dr Michael J Lloyd, MD 1055 N 300 W Ste 204, Provo, UT 84604-3374 Ph: (801) 357-7373 |
News Archive
The Muscular Dystrophy Association today celebrated news of the U.S. Food and Drug Administration's decision to grant approval for nusinersen (brand name Spinraza), the first disease-modifying drug to treat the most common genetic cause of death in infants.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells.
A study by a joint research team including professor Kazuyo Tsuzuki of Toyohashi University of Technology, Department of Architecture and Civil Engineering, National Institute of Advanced Industrial Science and Technology and Asahi Kasei Homes revealed that airflow from an air conditioner stimulates the human body while sleeping and impacts on sleep conditions even if the mean airflow velocity is lower than an insensible level.
Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' health habits and connections to caregivers.
› Verified 6 days ago
Jonathan B Gunther, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1735 N State St, Provo, UT 84604 Phone: 801-379-2904 Fax: 801-379-2959 | |
Thomas Dyreng Myers, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 280 River Park Dr, Suite 220, Provo, UT 84604 Phone: 801-224-3565 Fax: 801-224-3567 | |
Dr. Matthew Reed Parsons, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1735 N State St, Provo, UT 84604 Phone: 801-374-1818 Fax: 801-379-2959 | |
Dr. James G Theurer, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1735 N State St, Provo, UT 84604 Phone: 801-374-1818 Fax: 801-379-2959 | |
Norman Kent Linton, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1735 N State St, Provo, UT 84604 Phone: 801-374-1818 Fax: 801-374-0163 | |
Dr. Jack Dunyon Stringham Ii, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1055 N 300 W Ste 500, Provo, UT 84604 Phone: 801-357-7704 |